Adial Pharmaceuticals Inc
ADIL0.239USD
-0.007-2.92%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
5.71MMarket Cap
LossP/E TTM
More Details of Adial Pharmaceuticals Inc Company
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Adial Pharmaceuticals Inc Info
Ticker SymbolADIL
Company nameAdial Pharmaceuticals Inc
IPO dateJul 27, 2018
CEOClaiborne (Cary J)
Number of employees5
Security typeOrdinary Share
Fiscal year-endJul 27
Address1180 Seminole Trail
CityCHARLOTTESVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code22901
Phone14344229800
Websitehttps://www.adialpharma.com/
Ticker SymbolADIL
IPO dateJul 27, 2018
CEOClaiborne (Cary J)
Company Executives of Adial Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.80K
--
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
821.00
--
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
350.00
--
Mr. Robertson H. Gilliland
Mr. Robertson H. Gilliland
Independent Director
Independent Director
--
--
Mr. James W. Newman, Jr.
Mr. James W. Newman, Jr.
Independent Director
Independent Director
--
--
Mr. Vinay Shah
Mr. Vinay Shah
Chief Financial Officer
Chief Financial Officer
--
--
Mr. J. Kermit Anderson
Mr. J. Kermit Anderson
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
60.80K
--
Mr. Kevin Schuyler
Mr. Kevin Schuyler
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
821.00
--
Mr. Tony Goodman
Mr. Tony Goodman
Chief Operating Officer, Director
Chief Operating Officer, Director
350.00
--
Mr. Robertson H. Gilliland
Mr. Robertson H. Gilliland
Independent Director
Independent Director
--
--
Mr. James W. Newman, Jr.
Mr. James W. Newman, Jr.
Independent Director
Independent Director
--
--
Mr. Vinay Shah
Mr. Vinay Shah
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
1.86%
Armistice Capital LLC
1.40%
Geode Capital Management, L.L.C.
0.68%
The Vanguard Group, Inc.
0.65%
Citadel Advisors LLC
0.60%
Other
94.80%
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
1.86%
Armistice Capital LLC
1.40%
Geode Capital Management, L.L.C.
0.68%
The Vanguard Group, Inc.
0.65%
Citadel Advisors LLC
0.60%
Other
94.80%
Shareholder Types
Shareholders
Proportion
Hedge Fund
2.06%
Corporation
1.88%
Investment Advisor
1.13%
Investment Advisor/Hedge Fund
0.68%
Individual Investor
0.36%
Research Firm
0.06%
Other
93.82%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
33
944.43K
1.50%
--
2025Q3
33
944.43K
1.65%
+373.38K
2025Q2
38
571.05K
2.50%
-3.54K
2025Q1
39
574.59K
5.92%
+185.57K
2024Q4
40
638.99K
4.37%
+99.22K
2024Q3
41
539.76K
5.40%
+246.68K
2024Q2
45
293.30K
9.08%
+102.21K
2024Q1
45
191.09K
7.23%
-101.96K
2023Q4
47
264.60K
8.46%
+207.34K
2023Q3
47
57.35K
15.43%
-34.64K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Intracoastal Capital, L.L.C.
446.28K
2.04%
+446.28K
--
Jun 20, 2025
Armistice Capital LLC
336.31K
1.54%
+336.31K
--
Sep 30, 2024
Geode Capital Management, L.L.C.
68.85K
0.32%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
13.16K
0.06%
--
--
Jun 30, 2025
Claiborne (Cary J)
60.80K
0.28%
--
--
Jun 04, 2025
Manchester Capital Management LLC
48.10K
0.22%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
27.77K
0.13%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
12.39K
0.06%
-35.35K
-74.04%
Jun 30, 2025
Newman (James W. Jr.)
13.54K
0.06%
--
--
Jun 04, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Date
Type
Ratio
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
Aug 04, 2023
Merger
25→1
FAQs
Who are the top five shareholders of Adial Pharmaceuticals Inc?
The top five shareholders of Adial Pharmaceuticals Inc are:
Intracoastal Capital, L.L.C. holds 446.28K shares, accounting for 2.04% of the total shares.
Armistice Capital LLC holds 336.31K shares, accounting for 1.54% of the total shares.
Geode Capital Management, L.L.C. holds 68.85K shares, accounting for 0.32% of the total shares.
The Vanguard Group, Inc. holds 13.16K shares, accounting for 0.06% of the total shares.
Claiborne (Cary J) holds 60.80K shares, accounting for 0.28% of the total shares.
Intracoastal Capital, L.L.C. holds 446.28K shares, accounting for 2.04% of the total shares.
Armistice Capital LLC holds 336.31K shares, accounting for 1.54% of the total shares.
Geode Capital Management, L.L.C. holds 68.85K shares, accounting for 0.32% of the total shares.
The Vanguard Group, Inc. holds 13.16K shares, accounting for 0.06% of the total shares.
Claiborne (Cary J) holds 60.80K shares, accounting for 0.28% of the total shares.
What are the top three shareholder types of Adial Pharmaceuticals Inc?
The top three shareholder types of Adial Pharmaceuticals Inc are:
Intracoastal Capital, L.L.C.
Armistice Capital LLC
Geode Capital Management, L.L.C.
Intracoastal Capital, L.L.C.
Armistice Capital LLC
Geode Capital Management, L.L.C.
How many institutions hold shares of Adial Pharmaceuticals Inc (ADIL)?
As of 2025Q4, 33 institutions hold shares of Adial Pharmaceuticals Inc, with a combined market value of approximately 944.43K, accounting for 1.50% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.15%.
What is the biggest source of revenue for Adial Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Adial Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
